Braveheart’s board is made up of two executive directors and two non-executive directors.
We expect all our directors to devote as much time as is required to carry out the roles and responsibilities they have each agreed to take on. This generally means that Trevor Brown is full time and Vivian Hallam, Sue Hagan and Qu Li are part time.
You can read more about each of our directors below
Executive and non-executive directors are re-elected at least once every three years. You can inspect the letters of appointment for all Braveheart’s directors at our registered office during normal business hours.
The board meets at least eight times a year to formulate, review and approve the group’s strategy, budgets, performance, major capital expenditure and corporate actions. Meetings are open and constructive and every director participates fully.
The board also has an audit committee and a remuneration committee. As appointments to the board are made by the board as a whole there is no need for a nominations committee.
Trevor joined the Board of Braveheart as a Non-Executive Director with effect from 1 April 2014 and became the Chief Executive Officer on 21 August 2015. He has acted as a CEO, executive director and non-executive director for a wide range of both listed and private companies in a range of sectors over 40 years. This has provided him with a vast amount of experience through many long term economic and corporate life cycles that mean he is highly qualified to assess the opportunities and risks for both the Group and its portfolio of investee companies.
Trevor’s governance knowledge is maintained through regulatory updates by the companies NOMAD and his wide-ranging market experience is kept up to date through his continued participation in a variety of businesses where the Group has a holding and in other companies that are unconnected to the Group. Trevor is also currently a director of the company Imaging Biometrics Limited, listed on the LSE Main Market.
Viv is a Chartered Mechanical Engineer and has an MBA from Aston Business School. He joined Viking Fund Managers in 2003 following twenty years of senior management in international advanced engineering companies, including Sarna, GKN and GEC. There he was responsible for design, development and marketing of new products for the plastics, automotive and power industries.
Viv joined Braveheart in 2009 as investment fund manager, responsible for managing its FCA regulated funds and private client services. As well as his deep knowledge of technology business, he has extensive experience of AIM market regulations and reporting. He became Executive Director of Braveheart in 2017, responsible for the operational management of Braveheart and management of the Strategic Investments, has chaired the Groups AGMs for many years and attends the Group’s Audit and Compliance Committees. Viv maintains his governance knowledge through the companies NOMAD and regulatory updates for AIM companies, his technical knowledge by seminars and industry specialists.
Sue brings a wide range of experience in research, development and commercialisation of medical devices, in-vitro diagnostic (IVD) medical devices, therapeutics and related healthcare products, with over 25 years of experience in both listed and early-stage life sciences companies. She led early phase combination drug-device projects with Pfizer and was project manager for the development of a radiopharmaceutical oncology product into a first in human trial at Aphton Biopharma, a NASDAQ listed immunotherapeutic company, where she also led the Research and Development Laboratory. Sue brings particular expertise in regulatory affairs, early-stage clinical development, life sciences, risk management and development strategy. These skills support the Board’s oversight of healthcare and technology-focused investments.
Sue is a member and Chair of the Group’s Remuneration Committee and Audit and Compliance Committee, contributing actively to the Company’s governance, internal control and remuneration frameworks. She maintains her technical and governance knowledge through ongoing professional development, including sector-specific seminars and regulatory updates relevant to AIM companies.
Qu is an experienced entrepreneur, investor and businesswoman with over 30 years of experience in corporate mergers and acquisitions, development and restructuring, and financing and investments. Qu has worked across several business disciplines, including research and development, design and engineering, manufacturing and logistics, marketing and PR, and management and finance. She has led many turnkey transactions ranging from US$5million to US$100 million and she has raised over US$300 million over the past 15 years.
In September 2024, Qu was appointed a Non-Executive Director of Autins Group plc, to represent Braveheart’s major shareholding in that company and brings considerable experience in the automobile sector to that role. Her governance knowledge is maintained through regulatory updates by the companies NOMAD and her participation in a variety of businesses both within and outside the Group. Qu is a member of the Group’s Remuneration Committee and Audit and Compliance Committee